How many insider trades does FilingIQ track for COCP?

FilingIQ tracks 77 Form 4 insider transactions for COCP (Cocrystal Pharma, Inc.), covering filings from Mar 23, 2015 onwards. 1 of those were filed in the last 90 days.

Are COCP insiders net buyers or net sellers?

Across the full Form 4 history for COCP, 32 transactions (42%) were open-market purchases and 2 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does COCP insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is COCP in?

Cocrystal Pharma, Inc. (COCP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $13.65M.

COCP insider trading

NasdaqCM Healthcare

Cocrystal Pharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

42% / 3%

Market cap

$13.65M

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.

Company website: www.cocrystalpharma.com

COCP insider activity at a glance

FilingIQ has scored 77 insider transactions for COCP since Mar 23, 2015. The most recent filing in our index is dated Feb 24, 2026.

Across the full history, 32 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on COCP insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live COCP trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for COCP?: FilingIQ tracks 77 Form 4 insider transactions for COCP (Cocrystal Pharma, Inc.), covering filings from Mar 23, 2015 onwards. 1 of those were filed in the last 90 days.
Are COCP insiders net buyers or net sellers?: Across the full Form 4 history for COCP, 32 transactions (42%) were open-market purchases and 2 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does COCP insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is COCP in?: Cocrystal Pharma, Inc. (COCP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $13.65M.

Methodology & sources

Every COCP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.